Spontaneous reversibility of bone loss induced by gonadotropin-releasing hormone analog treatment.
article
OA: green
CC0
⤵ 29 in-corpus citations
AI-generated summary
Six months of GnRH-a treatment in young women caused temporary lumbar bone loss that fully reversed by 24 months after treatment withdrawal.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
OBJECTIVE: To verify if a 6-month period of hypoestrogenism due to chronic treatment with GnRH analogue (GnRH-a) causes irreversible bone loss in young women. DESIGN: Controlled clinical study in volunteer women. SETTING: Department of Obstetrics and Gynecology, University of Cagliari, Cagliari, Italy. PATIENTS: Twenty-eight women (mean age +/- SE 81.1 +/- 0.99 years) with endometriosis diagnosed by laparoscopy and 25 healthy, normally cycling women of the same age (28.3 +/- 1.14 years). INTERVENTIONS: In women with endometriosis, six SC implants of the GnRH-a compound, 3.6 mg goserelin acetate depot, were administered every 28 days starting within 15 days of laparoscopy. Compounds interfering with bone metabolism or hormonal formulations were not taken by control women during the entire period of the study. MAIN OUTCOME MEASURE: Evaluation of lumbar bone mineral density at the start of the study and 6, 12, and 30 months later. RESULTS: At the onset of the study, lumbar bone mineral density did not differ in women with endometriosis and control women. Lumbar bone mineral density values significantly decreased after 6 months of GnRH-a treatment. This reduction was still evident 6 months after GnRH-a interruption. However, 24 months after treatment withdrawal, bone mineral density reduction disappeared and bone mineral density values were completely superimposable (+/- O.4 percent) to those observed before treatment. In contrast, control women lumbar bone mineral density values did not change during the entire period of observation. CONCLUSIONS: These data suggest that GnRH-a treatment for 6 months is not associated with long-term effects on lumbar bone density.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (24)
- Bone mass in endometriosis patients treated with GnRH agonist implant or danazol. via openalex
- Bone Mineral Density of the Lumbar Spine in Endometriosis Subjects Compared to an Age-Similar Control Population* via openalex
- Changing concepts of medical treatment of endometriosis via openalex
- Gonadotropin-releasing hormone agonist plus estrogen-progestin “add-back” therapy for endometriosis-related pelvic pain via openalex
- Gonadotropin-releasing hormone agonists: Strategies formanaging the hypoestrogenic effects of therapy via openalex
- Goserelin (Zoladex ) depot in the treatment of endometriosis via openalex
- Hormone treatment of endometriosis: The estrogenthreshold hypothesis via openalex
- Is It Possible to Prevent Bone Loss in Young Women Treated with Luteinizing Hormone-Releasing Hormone Agonists? via openalex
- Nafarelin therapy in endometriosis: Long-term effects on bone mineral density via openalex
- Reduced Bone Mass in Reproductive-Aged Women with Endometriosis* via openalex
- Reversible bone loss in women treated with GnRH-agonists for endometriosis and uterine leiomyoma via openalex
- W2078632549 via openalex
- W2109034857 via openalex
- W1512318310 via openalex
- W2128241866 via openalex
- W2153895111 via openalex
- W2287757320 via openalex
- W2467395168 via openalex
- W2472762831 via openalex
- W1999502490 via openalex
- W2010663321 via openalex
- W1984155944 via openalex
- W2055260481 via openalex
- W2062982521 via openalex
Cited by (29)
- Use of gonadotropin-releasing hormone agonists for ovarian preservation in patients receiving cyclophosphamide for systemic lupus erythematosus: A meta-analysis 2022
- <p>Clinical Utility Of Elagolix As An Oral Treatment For Women With Uterine Fibroids: A Short Report On The Emerging Efficacy Data</p> 2019
- Repeated two cycles of ulipristal acetate treatment improve the quality of life in premenopausal women with heavy menstrual bleeding dependent on uterine myomas, without impairment of bone health 2019
- Emerging therapy for endometriosis 2015
- Comparison of complete and incomplete excision of deep infiltrating endometriosis. 2015
- An update on the pharmacological management of endometriosis 2013
- Gonadotropin releasing hormone agonists: Expanding vistas 2011
- Catamenial Pneumothorax: A Case Report and Review of the Literature 2008
- Expression und Regulation von Enzymen des Östrogenmetabolismus in humanen Endometriumläsionen kultiviert in der Nacktmaus 2007
- Treatment of dysfunctional uterine bleeding in the perimenopause: The effects of adding combined estradiol/norethisterone acetate therapy to goserelin acetate treatment – a randomized, placebo-controlled, double-blind trial 2006
- GnRH analogs: Options for endometriosis-associated pain treatment 2006
- GnRH agonist and antagonist: Options for endometriosis pain treatment 2006
- Long-term fracture risk among women with proven endometriosis 2006
- Treatment with leuprolide acetate and hormonal add-back for up to 10 years in stage IV endometriosis patients with chronic pelvic pain 2006
- Long-term effects on bone mineral density and bone metabolism of 6 months’ treatment with gonadotropin-releasing hormone analogues in Japanese women: comparison of buserelin acetate with leuprolide acetate 2005
- Use of a gonadotropin‐releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus 2005
- Painful menstruation: endometriosis 2005
- One year comparison between two add-back therapies in patients treated with a GnRH agonist for symptomatic endometriosis: a randomized double-blind trial 2004
- Efficacy of Interferential Current in the Treatment of Pelvic Pain Associated with Endometriosis 2004
- Diagnosis and treatment of endometriosis 2003
- Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: long-term follow-up*1 2002
- Bone metabolism in postmenopausal women who were treated with a gonadotropin-releasing hormone agonist and tibolone 2002
- Long-term use of gonadotropin-releasing hormone analogs and hormone replacement therapy in the management of endometriosis: a randomized trial with a 6-year follow-up 2000
- Gonadotropin-releasing hormone agonist plus “add-back” hormone replacement therapy for treatment of endometriosis: a prospective, randomized, placebo-controlled, double-blind trial 2000
- Endometriosis: An Overview of the Disease and Its Treatment 2000
- Aetiology and medical treatment of endometriosis 2000
- Effects of Add-Back Therapy on Bone Mineral Density and Pyridinium Crosslinks in Patients with Endometriosis Treated with Gonadotropin-Releasing Hormone Agonists 1999
- Women of Reproductive Age with Endometriosis are Not Osteopenic 1998
- GnRH agonists and add‐back therapy: is there a perfect combination? 1998
Source provenance
- europepmc
- last seen: 2026-06-04T01:30:01.192114+00:00
- openalex
- last seen: 2026-06-04T00:00:01.174412+00:00
- pubmed
- last seen: 2026-05-13T22:11:02.671803+00:00
License: CC0
· commercial use OK